期刊
EXPERT OPINION ON DRUG SAFETY
卷 20, 期 11, 页码 1299-1307出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14740338.2021.1962284
关键词
Acute respiratory distress syndrome; antiviral medication; coronavirus disease; COVID-19; GS-5734; pandemic; remdesivir; drug safety
Remdesivir has shown effectiveness in reducing recovery time and improving clinical outcomes in COVID-19 patients, particularly in those with early presentation and moderate disease. Despite not reducing mortality, it is well tolerated and has an acceptable safety profile in both pediatric and adult populations.
Introduction Remdesivir is a nucleoside analog that inhibits viral RNA replication by blocking RNA-dependent RNA polymerase. First developed and tested during the Ebola epidemic, repurposed, and gained prominence during the Coronavirus disease 19 (COVID-19) pandemic. Based on data from three major trials, remdesivir became the first and only medication to obtain approval from the Food and Drug Administration (FDA) to treat patients hospitalized with COVID-19 disease. Areas covered The purpose of the article is to review available preclinical, clinical, and post-marketing data to assess the safety and efficacy of remdesivir in the treatment of COVID-19 patients. We performed a comprehensive literature review of articles published on remdesivir until January 2021. Expert opinion The substantial evidence of its effectiveness in a few trials together with the favorable safety profile makes remdesivir a primary therapeutic candidate for treatment in adult and pediatric patients who are hospitalized with COVID-19 and requiring oxygen supplementation. While remdesivir does not improve mortality, it has been shown to reduce the recovery time and increase the odds for clinical improvement, specifically in patients with early presentation and moderate COVID-19 disease. Remdesivir is well tolerated and has an acceptable safety profile in the pediatric and adult populations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据